David Altshuler, Vertex CSO
September 16, 2020 05:00 PM EDTUpdated September 17, 06:38 AM
Deals
Cell/Gene Tx

Mod­er­na picks up a $75M cash wind­fall as long­time col­lab­o­ra­tor Ver­tex signs up for a gene edit­ing as­sault on cys­tic fi­bro­sis

John Carroll

Editor & Founder

Af­ter nail­ing down the top drug fran­chise in cys­tic fi­bro­sis, Ver­tex $VRTX is turn­ing to the mR­NA afi­ciona­dos at Mod­er­na $MR­NA to use gene edit­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times